Ugro Capital announces an acquisition

The Scheme does not provide a conventional share-swap ratio: no new UGRO Capital equity shares are to be issued as consideration for the merger of wholly owned Profectus Capital ^[1]. The shares held by UGRO in Profectus will instead be cancelled without further consideration ^[2].

Resulting dilution for existing UGRO shareholders: 0%. Since the transaction creates no additional UGRO equity shares, the post-merger share count is unchanged for dilution purposes.

The cited 18 August 2026 filing does not disclose the Scheme-level numbers required to answer this quantitatively. It confirms the proposed amalgamation of Profectus Capital Private Limited into UGRO Capital pursuant to the NCLT order dated 6 August 2026, but the extract contains no figures for Profectus’ AUM, GNPA, NNPA, pro-forma CRAR, or leverage ^[3].

Analytical implication: The acquisition will consolidate Profectus’ loan assets and liabilities into UGRO, but its effect on capital ratios cannot be inferred from AUM alone. Pro-forma CRAR would depend on the combination of post-merger eligible capital and risk-weighted assets, while leverage would depend on the acquired borrowings relative to consolidated net worth. The direction and magnitude of the change therefore require the Scheme’s explanatory statement or financial annexures containing the pro-forma balance sheet and capital-ratio calculations.

Thus, the transaction is confirmed, but the AUM, asset-quality profile and capital-structure impact are not quantifiable from the cited intimation.

RBI approval is not a remaining milestone: it was reportedly obtained on 25 February 2026, while NSE and BSE no-objection letters were received on 9 and 10 July 2026, respectively. ^[1]

As of the latest company filing, the 22 September 2026 meetings had been scheduled, not completed. UGRO’s equity shareholders, secured creditors and unsecured creditors were to vote on the scheme on that date. ^{[4] [5] [6]}

Remaining merger milestones

1. Completion and outcome of stakeholder meetings — including the required creditor and shareholder approvals. For Profectus, its equity-shareholder and unsecured-creditor meetings were reportedly dispensed with based on consent affidavits; a secured-creditor meeting remained directed. ^[7]

2. Submission of the meeting results and related documents to the NCLT, followed by the Tribunal’s substantive sanction of the Scheme. The NCLT’s 6 August 2026 order only directed the meetings; it did not itself consummate the amalgamation. The scheme still required meeting approvals and subsequent NCLT sanction. ^{[3] [7]}

3. Filing of the NCLT sanction order with the Registrar of Companies and completion of the consequential corporate and statutory filings. This is the step that would ordinarily make the sanctioned scheme effective, but the company announcement cited here does not specify the ROC filing date, statutory deadline or any additional filing checklist.

4. Post-effectiveness implementation, including cancellation of Profectus’s share capital and transfer/consolidation of its business and assets into UGRO. Since Profectus is wholly owned by UGRO, no merger consideration or new UGRO shares are expected under the disclosed scheme terms. ^[7]

Operational integration timeline

No management target for full operational integration is disclosed in the cited company filing or accompanying coverage. The disclosed appointed date is 1 April 2026 for scheme purposes, but that is not the same as a stated date for completing systems, processes, personnel or operating integration. ^[7]

The practical timing therefore remains conditional on:

• the 22 September meetings;
• NCLT sanction;
• ROC filing and scheme effectiveness; and
• management’s post-sanction integration execution.

The key distinction is that the regulatory path appears to have moved beyond RBI and exchange clearances, but the merger remains dependent on stakeholder approval, final NCLT sanction and effectiveness filings. A firm “fully operational” integration date cannot be attributed to management from the cited disclosures.